Therapeutic strategies for COVID-19: progress and lessons learned

G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19

Q Hu, Y Xiong, GH Zhu, YN Zhang, YW Zhang… - MedComm, 2022 - Wiley Online Library
The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …

Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review

X Li, Y Song - European Journal of Medicinal Chemistry, 2023 - Elsevier
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …

Biological and pharmacological aspects of tannins and potential biotechnological applications

LFM de Melo, VG de Queiroz Aquino-Martins… - Food Chemistry, 2023 - Elsevier
Secondary metabolites are divided into three classes: phenolic, terpenoid, and nitrogenous
compounds. Phenolic compounds are also known as polyphenols and include tannins …

Bioactive natural products in COVID-19 therapy

Z Wang, N Wang, L Yang, X Song - Frontiers in Pharmacology, 2022 - frontiersin.org
The devastating COVID-19 pandemic has caused more than six million deaths worldwide
during the last 2 years. Effective therapeutic agents are greatly needed, yet promising magic …

Perspectives on SARS-CoV-2 main protease inhibitors

K Gao, R Wang, J Chen, JJ Tepe… - Journal of medicinal …, 2021 - ACS Publications
The main protease (Mpro) plays a crucial role in severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) replication and is highly conserved, rendering it one of the …

Natural products, alone or in combination with FDA-approved drugs, to treat COVID-19 and lung cancer

L Yang, Z Wang - Biomedicines, 2021 - mdpi.com
As a public health emergency of international concern, the highly contagious coronavirus
disease 2019 (COVID-19) pandemic has been identified as a severe threat to the lives of …

Structural biology of SARS-CoV-2 Mpro and drug discovery

Y Duan, H Wang, Z Yuan, H Yang - Current Opinion in Structural Biology, 2023 - Elsevier
Since its outbreak in late 2019, the COVID-19 pandemic has drawn enormous attention
worldwide as a consequence of being the most disastrous infectious disease in the past …

Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro

L Lu, Y Peng, H Yao, Y Wang, J Li, Y Yang, Z Lin - Antiviral Research, 2022 - Elsevier
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) helicase NSP13 plays
a conserved role in the replication of coronaviruses and has been identified as an ideal …

A review of the current landscape of SARS-CoV-2 main protease inhibitors: Have we hit the bullseye yet?

G Macip, P Garcia-Segura, J Mestres-Truyol… - International journal of …, 2021 - mdpi.com
In this review, we collected 1765 severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) M-pro inhibitors from the bibliography and other sources, such as the COVID …